Moreover, from a therapeutic standpoint, the inhibition of a single mitoE3 could cause an increase in another one, in the context where two of them both act as oncogenes (for example, in breast cancer for MUL1 and MARCH5). Here, MARCHF5 is linked to breast carcinoma.